Evidence map›Paper›PMID 25058039›Full record

ArticlePloS one2014

Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

Irina Isakova-Sivak, Jørgen de Jonge, Tatiana Smolonogina, Andrey Rekstin, Geert van Amerongen, Harry van Dijken, Justin Mouthaan, Paul Roholl, Victoria Kuznetsova, Elena Doroshenko and 2 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Irina Isakova-SivakInstitute for Experimental Medicine, Saint Petersburg, Russia.
Jørgen de JongeCentre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.
Tatiana SmolonoginaInstitute for Experimental Medicine, Saint Petersburg, Russia.
Andrey RekstinInstitute for Experimental Medicine, Saint Petersburg, Russia.
Geert van AmerongenAnimal Research Center, InTraVacc, Bilthoven, the Netherlands.
Harry van DijkenCentre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.
Justin MouthaanCentre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands.
Paul RohollMicroscope Consultancy, Weesp, the Netherlands.
Victoria KuznetsovaInstitute for Experimental Medicine, Saint Petersburg, Russia.
Elena DoroshenkoInstitute for Experimental Medicine, Saint Petersburg, Russia.
Vadim TsvetnitskyPATH Vaccine Development Global Program, Seattle, Washington, United States of America.
Larisa RudenkoInstitute for Experimental Medicine, Saint Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic track record, H2N2 is regarded as a potential pandemic threat. To prepare for an H2N2 pandemic, here we developed and tested in mice and ferrets two live attenuated influenza vaccines based on the haemagglutinins of the two different H2N2 lineages that circulated at the end of the cycle, using the well characterized A/Leningrad/134/17/57 (H2N2) master donor virus as the backbone. The vaccine strains containing the HA and NA of A/California/1/66 (clade 1) or A/Tokyo/3/67 (clade 2) showed a temperature sensitive and cold adapted phenotype and a reduced reproduction that was limited to the respiratory tract of mice, suggesting that the vaccines may be safe for use in humans. Both vaccine strains induced haemagglutination inhibition titers in mice. Vaccination abolished virus replication in the nose and lung and protected mice from weight loss after homologous and heterologous challenge with the respective donor wild type strains. In ferrets, the live attenuated vaccines induced high virus neutralizing, haemagglutination and neuraminidase inhibition titers, however; the vaccine based on the A/California/1/66 wt virus induced higher homologous and better cross-reactive antibody responses than the A/Tokyo/3/67 based vaccine. In line with this observation, was the higher virus reduction observed in the throat and nose of ferrets vaccinated with this vaccine after challenge with either of the wild type donor viruses. Moreover, both vaccines clearly reduced the infection-induced rhinitis observed in placebo-vaccinated ferrets. The results favor the vaccine based on the A/California/1/66 isolate, which will be evaluated in a clinical study.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralDrug Evaluation, PreclinicalFemaleFerretsGene ExpressionHemagglutinins, ViralHumansImmunizationInfluenza A Virus, H2N2 SubtypeInfluenza VaccinesLungMiceMice, Inbred CBANeuraminidaseAntibodies, NeutralizingAntibodies, ViralHemagglutinins, ViralInfluenza VaccinesNeuraminidaseVaccines, Attenuated

Identifiers

PMID25058039
PMCPMC4109939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.